316 related articles for article (PubMed ID: 11758575)
1. FDA's role in administering the Hatch-Waxman Act.
Malkin BJ
Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
[No Abstract] [Full Text] [Related]
2. FDA's role in making exclusivity determinations.
Dickinson EH
Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
[No Abstract] [Full Text] [Related]
3. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
4. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
Srivastava D
Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
[No Abstract] [Full Text] [Related]
5. The Hatch-Waxman Act during patent prosecution and beyond.
Mahn TG
Food Drug Law J; 1999; 54(2):233-6. PubMed ID: 11758578
[No Abstract] [Full Text] [Related]
6. Navigating the Hatch-Waxman Act's safe harbor.
Jones PB
Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
[No Abstract] [Full Text] [Related]
7. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
8. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
9. GATT implementation and generic drug approval.
Safir PO; Lassman SM
Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
[No Abstract] [Full Text] [Related]
10. A new history and discussion of 180-day exclusivity.
Korn DE; Lietzan E; Scott SW
Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
[TBL] [Abstract][Full Text] [Related]
11. Overview of the Hatch-Waxman Act and its impact on the drug development process.
Mossinghoff GJ
Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
[No Abstract] [Full Text] [Related]
12. The History and Political Economy of the Hatch-Waxman Amendments.
Lietzan E
Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922
[No Abstract] [Full Text] [Related]
13. Patenting drug products: anticipating Hatch-Waxman issues during the claims drafting process.
Mahn TG
Food Drug Law J; 1999; 54(2):245-53. PubMed ID: 11758582
[No Abstract] [Full Text] [Related]
14. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
Lietzan EK
Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
[TBL] [Abstract][Full Text] [Related]
15. Teva v. Eisai: what's the real "controversy"?
Wang GL
Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
[TBL] [Abstract][Full Text] [Related]
16. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
17. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
Lewis RA
J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
[No Abstract] [Full Text] [Related]
18. Scientific and legal viability of follow-on protein drugs.
Dudzinski DM; Kesselheim AS
N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
[No Abstract] [Full Text] [Related]
19. Pharmaceutical trademarks: navigating through the FDA's pilot program.
Ferrer E
Drug News Perspect; 2010 Jun; 23(5):333-6. PubMed ID: 20603657
[TBL] [Abstract][Full Text] [Related]
20. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
[Next] [New Search]
